Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 7CNS 6Genitourinary 3NET 2Head & Neck 2Tumor-Agnostic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 1

Interventions

Fulvestrant 85Letrozole 79Paclitaxel 76pembrolizumab 72Specimen Handling 67Trastuzumab 62Carboplatin 57Magnetic Resonance Spectroscopy 52ribociclib 49Capecitabine 49Anastrozole 48pertuzumab 46palbociclib 45abemaciclib 41exemestane 40Tamoxifen 40Cyclophosphamide 40Biopsy 39trastuzumab deruxtecan 31Docetaxel 30Radiotherapy 29Taxes 28Gemcitabine 25Blood Specimen Collection 25130-nm albumin-bound paclitaxel 25Surveys and Questionnaires 23olaparib 22Standard of Care 22sacituzumab govitecan 20eribulin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
gallium Ga 68 dotatate × Breast × 90 days × Clear all
NCT04529044 2026-06-05

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

OHSU Knight Cancer Institute

Phase 2 Recruiting
10 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡